Biofrontera

Biofrontera FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 112.26 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 63.20 % — a change of 77.64% (higher).

FCF Conversion

112.26 %

YoY

77.64%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Biofrontera is 2025 112.26 % . FCF Conversion Rate (FCF/EBITDA) of Biofrontera was 2024 63.20 % . It decreases by 77.64% higher compared to the previous year.

The Biofrontera FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
157.10 EUR
Jan 1, 2019
472.25 EUR
Jan 1, 2020
27.82 EUR
Jan 1, 2021
78.97 EUR
Jan 1, 2022
11.04 EUR
Jan 1, 2023
766.67 EUR
Jan 1, 2024
63.20 EUR
Jan 1, 2025
112.26 EUR
The Biofrontera FCF Conversion history
YEARFCF ConversionYoY
112.26 %+77.64%
63.20 %-91.76%
766.67 %+6,844.34%
11.04 %-86.02%
78.97 %+183.87%
27.82 %-94.11%
472.25 %+200.61%
157.10 %+87.15%
83.94 %-20.88%
106.10 %+20.09%
88.34 %+17.05%
75.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

FCF Conversion Rate (FCF/EBITDA) of Biofrontera is 112.26 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Biofrontera changed from 63.20 % to 112.26 %, representing a 77.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Biofrontera since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Biofrontera with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biofrontera

All Key Metrics — Biofrontera